Azacitidine was also studied in combination with R-CHOP in a phase 1/2 trial (NCT01004991) that reported a CR rate of 91.7% in 12 untreated DLBCL patients. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.